- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:food:aim_health:aging [03.13.2019] – [with additional studies] sallieq | home:food:aim_health:aging [05.17.2019] – [Health Maintenance and Olmesartan] sallieq | ||
|---|---|---|---|
| Line 5: | Line 5: | ||
| Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
| taken from article [[home: | taken from article [[home: | ||
| + | |||
| + | < | ||
| ===== with additional studies ===== | ===== with additional studies ===== | ||
| Line 22: | Line 24: | ||
| Administration of olmesartan suppressed the accumulation of macrophages in brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed> | Administration of olmesartan suppressed the accumulation of macrophages in brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed> | ||
| - | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) | + | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pubmed> |
| Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. (({{pubmed> | Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. (({{pubmed> | ||
home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.